ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / XERS / earnings
SLS (38) SRPT (27) BRVE (46) TRVI (30) ⌘ Pro Terminal →

Xeris Biopharma Holdings Inc. (XERS) Next Earnings Date & Expected ±8.7% Move

$10.71 -0.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.68

Xeris Biopharma Holdings Inc. (XERS) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →
ROARABLE C • HOLD / WATCH Cap $1.95B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XERS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.71 (-0.37% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, XERS ranks #128 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XERS compare to SLS and SRPT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XERS?
▼

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.68 (-0.26%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D+
Cash (16)Whales (16)SEC (12)Macro (9)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$13 Bull$11 Base$9 Bear
📬 FREE XERS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XERS)Realized 20D OHLCV Swing Band: ±8.7%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY XERS SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 9.8% FCF Margin ($28.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±8.7% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (59.7) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$10.20+9.1% Next Q
Q2 (-2Q)
59
Grade C$11.13-6.1% Next Q
Q3 (-1Q)
61
Grade C$10.45+2.5% Next Q
Current
64
Grade C$10.71+1.1% Hist 90D α
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the XERS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, XERS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.39) or 200D SMA ($7.53) invalidates the momentum regime and cuts Target Base ($11.00) toward Bear Floor ($8.58).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±8.7% Swing Band

±$0.93 Expected Swing
$9.78 (-8.7%)Spot $10.71$11.64 (+8.7%)
MODEL EARNINGS SETUP GAUGE

XERS Quantitative Pre-Earnings Setup: 64/100

Trailing EPS: $4.25 • YoY Revenue Growth: 43.7%

Model Bullish Setup (64/100)Model Risk Weight (36/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$291.8M$554.0K$28.6M52%
FY 20242024-12-31$203.1M-$54.8M-$37.0M52%
FY 20232023-12-31$163.9M-$62.3M-$47.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating XERS & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on XERS
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +68.93%▲ ASCENDING CHANNEL
2026-11-03O $10.75H $10.75L $10.71C $10.71VOL 1.55M
RES: $12.31SUP: $8.25SMA50: $9.39SMA200: $7.53
$11.81$10.19$8.56$6.93$5.31RES $12.31SUP $8.25$10.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XERS Butterfly Map → + Track XERS →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth

vs. +43.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XERS)

Health Care Rank #128 of 1016 ⚔️ SLS vs XERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XERS vs. SLS, SRPT, BRVE, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xeris Biopharma Holdings Inc. (XERS) ranks #128 by composite RQD confidence (64/100, grade C) and #260 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, XERS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently leads its immediate peer cohort in composite quantitative strength at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XERS ACTIVE
Xeris Biopharma Holdings Inc.
C 64/100 — — 16.0% -0.37% $1.95B Benchmark Subject
SLS
SELLAS Life Sciences Group Inc.
D- 38/100 — — -21.8% -4.68% $1.95B /sls-vs-xers →
SRPT
Sarepta Therapeutics Inc.
E 27/100 — 96.0% -35.0% -3.17% $1.97B /srpt-vs-xers →
BRVE
Braveheart Bio Inc.
D 46/100 — — — +1.51% $1.94B /brve-vs-xers →
TRVI
Trevi Therapeutics Inc.
E 30/100 — — -23.7% -1.81% $1.93B /trvi-vs-xers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867096

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported GAAP revenue of $291.8M (+43.7% vs. FY2024 revenue of $203.1M , and +78.0% cumulative change since FY2023) , GAAP net income of $554.0K, operating cash flow of $28.6M, and free cash flow of $28.6M (+177.4% YoY). On the balance sheet, XERS closed FY2025 with $383.5M in total assets against $220.3M in total debt (Altman Z-Score: 2.11, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $291.8M $554.0K $28.6M $28.6M $383.5M $220.3M
FY2024 (FY) 2024-12-31 $203.1M -$54.8M -$37.0M -$37.0M $323.1M $217.0M
FY2023 (FY) 2023-12-31 $163.9M -$62.3M -$47.0M -$47.0M — —

3. XERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.71 (-0.37% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, XERS ranks #128 in composite RQD confidence.

How does XERS compare to SLS and SRPT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XERS?

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XERS trading relative to its 50-day, 200-day, and 52-week technical levels?

XERS last traded at $10.71 (-0.37% on volume of 1,550,345 shares), positioning the stock +14.06% above its 50-day simple moving average ($9.39) and +42.23% above its 200-day simple moving average ($7.53). Across its 52-week range of $5.25 to $11.42, XERS sits at the 88.5% percentile with a 14-day RSI of 59.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.7% ($9.78 to $11.64).

XERS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is XERS's next earnings date?

Based on SEC filing cadence, Xeris Biopharma Holdings Inc. (XERS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is XERS stock expected to move on earnings?

Volatility modeling currently projects a ±8.7% event move for XERS, spanning a range between $9.78 and $11.64.

Direct Sub-Reports: XERS RQD Cockpit XERS 12M Forecast XERS Earnings & Move XERS Dividends & DRIP XERS Insiders & 13F XERS Whale Options XERS Profit Sankey XERS News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

XERS — Xeris Biopharma Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:27:12Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, XERS scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine 16/20 (ROIC 16%; FCF yield 1.46%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 11/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet 12/20 (Altman Z 2.11; Piotroski F 7/9; Debt/Equity 8.5).

For a prospective investor, the profile is mixed. The strongest pillars are the cash-generation and institutional-flow scores, which point to upside drivers: the reported ROIC of 16% and the institutional accumulation signal. The weakest pillar is Macro Regime Fit at 9/20, which implies that the stock's sensitivity to sector and market conditions offers limited cushion in a downturn. Insider conviction at 11/20 is middling, suggesting insider flow neither strongly confirms nor contradicts the thesis. The 1.46% FCF yield and EV/EBITDA of 83.1 indicate that valuation is demanding relative to current cash generation, so a re-rating depends on sustained earnings growth. The Debt/Equity reading of 8.5 and the forensic score of 12/20 call for close monitoring of leverage. The verdict label is a rating-system output and is not a personalized recommendation.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$291.8M$24.9M$0.6MN/A$28.6M$111.0M$220.3M
FY 2024$203.1M$-33.6M$-54.8MN/A$-37.0M$71.6M$217.0M
FY 2023$163.9M$-44.0M$-62.3MN/A$-47.0MN/AN/A

Per the SEC financials, revenue rose from $163.9M in FY 2023 to $291.8M in FY 2025, and FY 2025 operating income of $24.9M compares with losses in the prior two years. Per the market data, the operating margin is 8.5%, the net margin 0.2%, and the gross margin 0%. Per the Roarable RQD rating, ROIC is 16% and the Altman Z-Score is 2.11; the Piotroski F-Score is 7/9 and Debt/Equity is 8.5. Cash of $111.0M against debt of $220.3M in FY 2025 indicates net debt, while the FY 2025 FCF of $28.6M is positive after two years of negative free cash flow.

Open Questions

  • What are the company's products, revenue sources, and customer concentration? (Not in source data.)
  • What were the drivers of the swing from FY 2024 losses to FY 2025 profit, and are they repeatable?
  • What are the debt maturities and interest terms behind the $220.3M debt balance, and how is it serviced?
  • What were the outcomes of the Q2 2026 earnings call, and do they confirm the FY 2025 trajectory?
  • What is the trailing and forward EPS, given that EPS is unreported across all periods?

XERS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xeris Biopharma Holdings Inc. (XERS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XERS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XERS Bull vs. Bear Conversation Board — What's Your Call at $10.71?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XERS 🐻 50% BEARISH CONVICTION
1. Pick Your Side on XERS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $11.61 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is XERS (C • RQD 64/100) a Buy at $10.75?

Welcome to the XERS (Xeris Biopharma Holdings Inc.) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (16.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.06 (-25.0%)
Spot @ $10.75

Pump the brakes on XERS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on XERS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Xeris Biopharma Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.76 (+28.0%)
Spot @ $10.75

XERS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on XERS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.75 (52-wk range $5.25 - $11.42), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%